US Food and Drug Administration (FDA) regulations allow human drug compounding — in which licensed pharmacists or physicians ...
Hims & Hers (HIMS) has launched an online GLP-1 supply tracker where people can share information about where the popular ...
Hims & Hers Health launched a GLP-1 Supply Tracker to spotlight challenges in accessing obesity medications, addressing ...
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...
The effects last only for a few hours. Examples include exenatide and lixisenatide. Ozempic: Novo Nordisk’s name-brand ...
Hosted on MSN23h
Ozempic on steroids? Successor that could cut down weight in half the time coming soonOn a call with investors last week, Danish drugmaker Novo Nordisk shared some teasers about CagriSema, the next generation of ...
Insider Monkey on MSN1d
Novo Nordisk A/S (NVO): A Bull Case TheoryNovo Nordisk A/S (NVO)'s share was trading at $109.09 as of Nov ... Driving NVO’s wide moat is a robust innovation pipeline ...
Diabetes and weight-loss drug tirzepatide (Mounjaro, Zepbound) was listed as a contributing factor in the death of a 58-year-old nurse from Scotland who died of multiple organ failure, septic shock, ...
If you said diabetes, you're right -- a new study finds diabetes costs $101 billion annually in diagnosis and treatment and ...
SAN ANTONIO -- Research presented at the ObesityWeek annual meeting included studies on rationing of prescription medications ...
Analyst Michael Nedelcovych from TD Cowen maintained a Buy rating on Novo Nordisk (NVO – Research Report) and keeping the price target at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback